rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

EcoR1 Capital, LLC

10% owner

Company insider

Files Form 4 as: 10% owner, Atara Biotherapeutics; 10% owner, First Tracks Biotherapeutics; Director, Aktis Oncology; 10% owner, Adaptimmune Therapeutics; Director and 10% owner, Zymeworks; 10% owner, iTeos Therapeutics; 10% owner, Prothena Corporation; Director and 10% owner, AnaptysBio.

Every Form 4 they filed

In numbers

Trades disclosed
137
Buys
73
Sells
22
Bought
$374.7M
Sold
$287.7M
Companies
17
Companies where not an officer
17
First trade
26 Mar 2014
Last trade
7 May 2026
Last filed
11 May 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
ATRA Atara Biotherapeutics10% owner · Biotechnology · last 7 May 20261 buy · 0 sells
TRAX First Tracks Biotherapeutics10% owner · Biotechnology · last 20 Apr 20260 buys · 1 sell
AKTS Aktis OncologyDirector · Biotechnology · last 12 Jan 20261 buy · 0 sells
Adaptimmune Therapeutics10% owner · last 30 Jul 20250 buys · 3 sells
ZYME ZymeworksDirector, 10% owner · Biotechnology · last 19 May 202540 buys · 0 sells
iTeos Therapeutics10% owner · last 15 May 20252 buys · 0 sells
PRTA Prothena Corporation10% owner · Biotechnology · last 6 May 202510 buys · 4 sells
ANAB AnaptysBioDirector, 10% owner · Biotechnology · last 2 Jan 20258 buys · 1 sell
Mersana Therapeutics10% owner · last 19 Dec 20240 buys · 0 sells
TNGX Tango Therapeutics10% owner · Biotechnology · last 7 Nov 20240 buys · 2 sells
VYGR Voyager Therapeutics10% owner · Biotechnology · last 11 Jan 20232 buys · 3 sells
Odonate Therapeutics10% owner · last 10 Dec 20211 buy · 3 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
2011Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
7 May 2026filed 11 May 2026ATRA Atara BiotherapeuticsBiotechnologySEC FORM 4 Bought$4.7M507,407 at $9.35filing
7 May 2026filed 11 May 2026ATRA Atara BiotherapeuticsBiotechnologySEC FORM 4 Bought$4.7M507,407 at $9.35filing
20 Apr 2026filed 22 Apr 2026TRAX First Tracks BiotherapeuticsBiotechnologySEC FORM 4 Sold$65.0M4,705,575 at $13.81filing
20 Apr 2026filed 22 Apr 2026TRAX First Tracks BiotherapeuticsBiotechnologySEC FORM 4 Sold$65.0M4,705,575 at $13.81filing
12 Jan 2026filed 12 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Code C—2,270,879filing
12 Jan 2026filed 12 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—102,500filing
12 Jan 2026filed 12 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—965,190filing
12 Jan 2026filed 12 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—86,222filing
12 Jan 2026filed 12 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Code C—202,862filing
12 Jan 2026filed 12 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Code C—128,506filing
12 Jan 2026filed 12 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Bought$37.4M2,077,779 at $18.00filing
12 Jan 2026filed 12 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Bought$2.6M144,443 at $18.00filing
12 Jan 2026filed 12 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—9,913,810filing
12 Jan 2026filed 12 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—997,299filing
12 Jan 2026filed 12 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—488,891filing
12 Jan 2026filed 12 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—2,397,500filing
30 Jul 2025filed 30 Jul 2025Adaptimmune TherapeuticsSEC FORM 4 Sold$2.7M27,433,338 at $0.10filing
29 Jul 2025filed 30 Jul 2025Adaptimmune TherapeuticsSEC FORM 4 Sold$269K2,687,460 at $0.10filing
28 Jul 2025filed 30 Jul 2025Adaptimmune TherapeuticsSEC FORM 4 Sold$3.7M33,931,740 at $0.11filing
19 May 2025filed 19 May 2025ZYME ZymeworksBiotechnologySEC FORM 4 Bought$70K5,919 at $11.78filing

Sectors

Health Care81
Not placed14

Buys in green, sells in red, by the company’s sector.

Related people

Akos CzibereChief Medical Officer · Chief Medical Officer at Aktis Oncology, filing Form 4 there in the last year
John A. OrwinDirector · Director at First Tracks Biotherapeutics, filing Form 4 there in the last year
Brian N. CherryDirector · Director at Atara Biotherapeutics, filing Form 4 there in the last year
J. Anthony WareDirector · Director at First Tracks Biotherapeutics, filing Form 4 there in the last year
AnhCo NguyenPresident and CEO · President and CEO at Atara Biotherapeutics, filing Form 4 there in the last year
William P. Scully10% owner · Also traded PRTA in the last 90 days
Adam SchayowitzEVP, Head of R&D · Also traded ZYME in the last 90 days
Adam CrystalPresident, R&D · Also traded TNGX in the last 90 days